SELE and acute myeloid leukemia: We find absence (in Sele−/− hosts), or therapeutic blockade of E-selectin (using small molecule antagonist GMI-1271/Uproleselan), at the same time as chemotherapy specifically sensitizes AML regenerating cells (LRC) and significantly improves overall treatment efficacy and mouse survival.